avp-21d9
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01202695)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Protective antigenINHIBITOR
pagA inhibitor
- Anthrax lethal factorINHIBITOR
lef inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109303 ↗
Also known as
- avp-21d9
- avp-21d9
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01202695 | Phase 1 | Aug 1, 2010 | Emergent BioSolutions, National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emergent BioSolutions | For profit | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1